Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00092482 |
The purpose of the study is to determine if an investigational vaccine with a single component develops an immune response that is similar to the equivalent investigational vaccine with four components to reduce cervical disease.
Condition | Intervention | Phase |
---|---|---|
Cervical Cancer Genital Warts |
Biological: V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Immunogenicity and Safety of Gardasil (V501) Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Consistency Lots for 16- to 23-Year-Old Women With and Additional Immunogenicity Bridge to the Monovalent HPV 16 Vaccine Pilot Manufacturing Lot Study-The F.U.T.U.R.E. Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease) |
Ages Eligible for Study: | 16 Years to 23 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 2004_080 |
Study First Received: | September 22, 2004 |
Last Updated: | May 17, 2007 |
ClinicalTrials.gov Identifier: | NCT00092482 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Virus Diseases Skin Diseases, Infectious Sexually Transmitted Diseases, Viral Warts Skin Diseases Condylomata Acuminata |
Condyloma Acuminatum Sexually Transmitted Diseases Condyloma DNA Virus Infections Papillomavirus Infections |
Skin Diseases, Viral Virus Diseases Skin Diseases, Infectious Sexually Transmitted Diseases, Viral Warts Skin Diseases |
Condylomata Acuminata Sexually Transmitted Diseases Tumor Virus Infections DNA Virus Infections Papillomavirus Infections |